BioCentury | Jan 3, 2019
Distillery Therapeutics

Neurology

INDICATION: Fragile X syndrome Mouse studies suggest an FMR1 peptide could help treat fragile X syndrome. In a mouse model of fragile X syndrome, a 298-mer human FMR1 peptide containing the N-terminal domain normalized the...
BioCentury | Nov 16, 2018
Financial News

Neurology company Cadent emerges with $40M series B

Cadent Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with news of a $40 million tranched series B round to bring its lead compound through Phase II trials to treat essential tremor and spinocerebellar ataxia (SCA)....
BioCentury | Nov 15, 2018
Financial News

Neurology company Cadent emerges with $40M series B

Cadent Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with news of a $40 million tranched series B round to bring its lead compound through Phase II trials to treat essential tremor and spinocerebellar ataxia (SCA)....
BioCentury | Aug 31, 2018
Company News

Urovant gets rights to gene therapy for overactive bladder

...who have failed oral pharmacologic therapy. hMaxi-K delivers a splice variant of the potassium channel KCa1.1 (KCNMA1; SLO...
...Ion Channel Innovations LLC, Ardsley, N.Y. Urovant Sciences Ltd., Basel, Switzerland Business: Genitourinary Alicia Parker Urovant Sciences Ltd. Potassium channel KCa1.1 (KCNMA1) (SLO) hMaxi-K Ion...
BioCentury | Aug 28, 2018
Company News

Roivant units Urovant, Dermavant in deals as NEA’s Torti joins ‘vant’ team

...who have failed oral pharmacologic therapy. hMaxi-K delivers a splice variant of the potassium channel KCa1.1 (KCNMA1; SLO...
BioCentury | Jun 28, 2018
Distillery Techniques

Biomarkers

...124 of which were previously unreported, including cytochrome P450 26A1 (CYP26A1; CP26) (rs17382981), potassium channel KCa1.1 (KCNMA1; SLO...
...Klaver, Erasmus University Rotterdam, Rotterdam, the Netherlands email: c.c.w.klaver@erasmusmc.nl Mark Zipkin Erasmus University Rotterdam Cytochrome P450 26A1 (CYP26A1) (CP26) Potassium channel KCa1.1 (KCNMA1) (SLO) v-maf...
BioCentury | May 24, 2018
Translation in Brief

Channel for T cell invasion

University of Cincinnati researchers have found that increasing potassium flux through the KCa3.1 channel could boost CD8 + T cell migration into the tumor microenvironment, raising the prospect that this could present a new mechanism...
BioCentury | Jan 5, 2018
Company News

Mallinckrodt acquiring Sucampo

...NYSE:MNK), Staines-upon-Thames, U.K. Business: Ophthalmic, Gastrointestinal, Endocrine/Metabolic Chris Lieu Amitiza lubiprostone Rescula unoprostone isopropyl Mallinckrodt plc Sucampo Pharmaceuticals Inc. Chloride channel 2 (CLCN2) (ClC-2) Potassium channel KCa1.1 (KCNMA1) (SLO)...
BioCentury | Dec 26, 2017
Company News

Mallinckrodt acquiring Sucampo

...$0.92 to end the week at $22.56. Chris Lieu Amitiza lubiprostone Rescula unoprostone isopropyl Mallinckrodt plc Sucampo Pharmaceuticals Inc. Chloride channel 2 (CLCN2) (ClC-2) Potassium channel KCa1.1 (KCNMA1) (SLO)...
BioCentury | Sep 29, 2017
Financial News

SpringWorks launches with $103M series A

On Sept. 25, SpringWorks Therapeutics LLC (New York, N.Y.) spun out of Pfizer Inc. (NYSE:PFE) with a tranched $103 million series A round led by Bain Capital Life Sciences, Bain Capital Double Impact and OrbiMed....
Items per page:
1 - 10 of 33